Who Paid My Doc
Young Jun
Oral & Maxillofacial Surgery Placentia, CA Doctor of Dentistry
NPI 1417103946 CMS profile 154419
601 E Yorba Linda Blvd, 9, Placentia, CA 92870
General payments
$14,341
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Young Jun of Placentia, CA is reported in the CMS Open Payments database as having received $14,341 across 84 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 94th percentile of Oral & Maxillofacial Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,241 | 5 | |
| 2024 | General | $235 | 10 | |
| 2023 | General | $2,735 | 14 | |
| 2022 | General | $753 | 13 | |
| 2021 | General | $3,097 | 13 | |
| 2020 | General | $1,853 | 9 | |
| 2019 | General | $1,426 | 20 |
Beside peers
- Young Jun
- Oral & Maxillofacial Surgery median
- Middle half of Oral & Maxillofacial Surgery
- National median
In program year 2025, general payments to Young Jun were reported at $4,241. Among 792 Oral & Maxillofacial Surgery profiles paid that year, the median was $184 and the middle half received between $61 and $541.
Show as a table
| Year | Young Jun | Oral & Maxillofacial Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,426 | $178 | $56–$584 | $163 |
| 2020 | $1,853 | $106 | $38–$316 | $114 |
| 2021 | $3,097 | $165 | $57–$511 | $132 |
| 2022 | $753 | $173 | $63–$494 | $149 |
| 2023 | $2,735 | $184 | $62–$521 | $160 |
| 2024 | $235 | $197 | $65–$603 | $164 |
| 2025 | $4,241 | $184 | $61–$541 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
744
Drug cost
$3,132
Branded share of claims
11.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Amoxicillin | Generic | 323 | $1,261 | |
| Ibuprofen | Generic | 218 | $684 | |
| Clindamycin Hcl | Generic | 83 | $447 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 58 | $355 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 28 | $307 | |
| Tramadol Hcl | Generic | 34 | $80 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 600 Part D prescribers listed as Oral & Maxillofacial Surgery; they describe a distribution and say nothing about conduct.
Records
84 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Oral & Maxillofacial Surgery in California
Tara Aghaloo
Oral & Maxillofacial Surgery · Los Angeles, CA
Trent Westernoff
Oral & Maxillofacial Surgery · Laguna Niguel, CA
Heshaam Fallah
Oral & Maxillofacial Surgery · Oakland, CA
Eric Baker
Oral & Maxillofacial Surgery · Dana Point, CA
Hamid Hajarian
Oral & Maxillofacial Surgery · Fountain Valley, CA
Karl Bruckman
Oral & Maxillofacial Surgery · Palo Alto, CA
Related records
Oral & Maxillofacial Surgery in California
Practitioners in the same specialty and state, ranked by reported value.
All Oral & Maxillofacial Surgery
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.